Cargando…

Glycation in Huntington’s Disease: A Possible Modifier and Target for Intervention

Glycation is the non-enzymatic reaction between reactive dicarbonyls and amino groups, and gives rise to a variety of different reaction products known as advanced glycation end products (AGEs). Accumulation of AGEs on proteins is inevitable, and is associated with the aging process. Importantly, gl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brás, Inês Caldeira, König, Annekatrin, Outeiro, Tiago Fleming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839463/ https://www.ncbi.nlm.nih.gov/pubmed/31322580 http://dx.doi.org/10.3233/JHD-190366

Ejemplares similares

Alpha-Synuclein Glycation and the Action of Anti-Diabetic Agents in Parkinson’s Disease
por: König, Annekatrin, et al.
Publicado: (2018)

Glycation potentiates neurodegeneration in models of Huntington’s disease
por: Vicente Miranda, Hugo, et al.
Publicado: (2016)

Glycation modulates alpha-synuclein fibrillization kinetics: A sweet spot for inhibition
por: Farzadfard, Azad, et al.
Publicado: (2022)

Production of Recombinant Alpha-Synuclein: Still No Standardized Protocol in Sight
por: Al-Azzani, Mohammed, et al.
Publicado: (2022)

Contribution of Neuroepigenetics to Huntington’s Disease
por: Francelle, Laetitia, et al.
Publicado: (2017)

Alpha-Synuclein: Mechanisms of Release and Pathology Progression in Synucleinopathies
por: Brás, Inês C., et al.
Publicado: (2021)

RAGE Against the Glycation Machine in Synucleinopathies: Time to Explore New Questions
por: Gelain, Daniel Pens, et al.
Publicado: (2023)

SUMO-modifying Huntington’s disease
por: Soares, Ericks S., et al.
Publicado: (2022)

Beyond Motor Deficits: Environmental Enrichment Mitigates Huntington’s Disease Effects in YAC128 Mice
por: Plácido, Evelini, et al.
Publicado: (2023)

More than meets the eye in Parkinson’s disease and other synucleinopathies: from proteinopathy to lipidopathy
por: Flores-Leon, Manuel, et al.
Publicado: (2023)

Huntington's disease: the case for genetic modifiers
por: Gusella, James F, et al.
Publicado: (2009)

Dicarbonyls and Advanced Glycation End-Products in the Development of Diabetic Complications and Targets for Intervention
por: Brings, Sebastian, et al.
Publicado: (2017)

Drug Targeting of α-Synuclein Oligomerization in Synucleinopathies
por: Outeiro, Tiago Fleming, et al.
Publicado: (2008)

Glycation modulates glutamatergic signaling and exacerbates Parkinson’s disease-like phenotypes
por: Chegão, Ana, et al.
Publicado: (2022)

Current and Possible Future Therapeutic Options for Huntington’s Disease
por: Ferguson, Mackenzie W., et al.
Publicado: (2022)

The alpha-synuclein oligomers activate nuclear factor of activated T-cell (NFAT) modulating synaptic homeostasis and apoptosis
por: Sant’Anna, Ricardo, et al.
Publicado: (2023)

The courage to change science
por: Outeiro, Tiago Fleming
Publicado: (2020)

Alpha-Synuclein Antibody Characterization: Why Semantics Matters
por: Outeiro, Tiago Fleming
Publicado: (2021)

ATP13A2 and Alpha-synuclein: a Metal Taste in Autophagy
por: Lopes da Fonseca, Tomás, et al.
Publicado: (2014)

Translational research in Huntington’s disease: opening up for disease modifying treatment
por: Burgunder, Jean-Marc
Publicado: (2013)

SIRT1 and SIRT2: emerging targets in neurodegeneration
por: Donmez, Gizem, et al.
Publicado: (2013)

Pharmacological Modulators of Tau Aggregation and Spreading
por: Dominguez-Meijide, Antonio, et al.
Publicado: (2020)

Role of advanced glycation end products in mobility and considerations in possible dietary and nutritional intervention strategies
por: Chen, Jie-Hua, et al.
Publicado: (2018)

Ubiquitin-modifying enzymes in Huntington’s disease
por: Sap, Karen A., et al.
Publicado: (2023)

Editorial: New insight into Huntington's disease: From neuropathology to possible therapeutic targets
por: Estrada-Sánchez, Ana María, et al.
Publicado: (2023)

Targeting Huntington’s disease through histone deacetylases
por: Gray, Steven G.
Publicado: (2011)

Novel targets for Huntington’s disease: future prospects
por: Mason, Sarah L, et al.
Publicado: (2016)

Therapeutic Targeting of Rab GTPases: Relevance for Alzheimer’s Disease
por: Jordan, Kate L., et al.
Publicado: (2022)

Current Diagnostic Methods and Non-Coding RNAs as Possible Biomarkers in Huntington’s Disease
por: Pellegrini, Miguel, et al.
Publicado: (2022)

Stem Cell Therapies in Movement Disorders: Lessons from Clinical Trials
por: Marsili, Luca, et al.
Publicado: (2023)

Psychological Interventions for People with Huntington’s Disease: A Call to Arms
por: Zarotti, Nicolò, et al.
Publicado: (2020)

Copy-number variation of the neuronal glucose transporter gene SLC2A3 and age of onset in Huntington's disease
por: Vittori, Angelica, et al.
Publicado: (2014)

Dystonia in Pediatric Huntington's Disease; Prominent and Possibly Painful
por: Ketels, Marjolein M.A., et al.
Publicado: (2023)

The Interplay between Alpha-Synuclein Clearance and Spreading
por: Lopes da Fonseca, Tomás, et al.
Publicado: (2015)

Assessing the Subcellular Dynamics of Alpha-synuclein Using Photoactivation Microscopy
por: Gonçalves, Susana, et al.
Publicado: (2013)

SIRT2 as a Therapeutic Target for Age-Related Disorders
por: de Oliveira, Rita Machado, et al.
Publicado: (2012)

Glycation Damage: A Possible Hub for Major Pathophysiological Disorders and Aging
por: Fournet, Maxime, et al.
Publicado: (2018)

Irritability in Huntington’s Disease
por: Karagas, Nicholas E., et al.
Publicado: (2020)

Glucocerebrosidase mutations disrupt the lysosome and now the mitochondria
por: Klein, Andrés D., et al.
Publicado: (2023)

Huntington’s Disease: The Past, Present, and Future Search for Disease Modifiers
por: Clabough, Erin B.D.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_o3l2dnbriant26m9sr9t7ovgba